Document is current

Article History

First Online: 8 December 2020

Declarations

:

: Jerold Chun has received consulting fees or research support from Abbott, AbbVie, Amira, Arena Pharmaceuticals, Biogen Idec, BiolineRX, Blade Therapeutics, Brainstorm Cell Therapeutics, Celgene, GlaxoSmithKline, Inception Sciences, Johnson & Johnson, Merck, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, SKAI Ventures and Taisho Pharmaceutical Co. Gavin Giovannoni has received speaker honoraria and consulting fees from AbbVie, Actelion, Almirall, Atara Bio, Bayer Schering Pharma, Biogen Idec, Five Prime, GlaxoSmithKline, GW Pharmaceuticals, Ironwood, Merck & Co., Merck KGaA, Novartis, Pfizer Inc., Protein Discovery Laboratories, Sanofi-Genzyme, Teva Pharmaceutical Industries Ltd, UCB and Vertex Pharmaceuticals. Samuel F. Hunter reports having served as a consultant for AbbVie, Bayer, Genentech/Roche and Sanofi-Genzyme; participation in clinical research trials for Actelion, Adamas, Genentech/Roche, Osmotica and Teva; receipt of research grant support from Sanofi-Genzyme; serving on speakers’ bureaux for Mallinckrodt, Novartis, Sanofi-Genzyme and Teva.

: Medical writing assistance was provided by Dr Ian M. Williams of Oxford PharmaGenesis, Oxford, UK, and supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Open-access publication was funded by Novartis Pharmaceuticals Corporation.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no datasets were generated or analysed for this review.

: All authors contributed equally to the conception of this work, the interpretation of the literature and the drafting of the manuscript. All authors critically revised the review for intellectual content and approved the final manuscript for publication.